Mr. Bandy brings extensive leadership experience in health care, specifically in the bariatric and minimally invasive surgery segments. Most recently, Mr. Bandy was President and Chief Executive officer of BroadSpot Imaging Corporation, a privately held ophthalmic imaging company, and prior to that he was President of the Wellness Division at Alphaeon Corporation. He previously spent 10 years as the senior executive leading the Inamed and Allergan Health Divisions through the launch, growth and transition of LAP-BAND®. Mr. Bandy formerly held positions of increased responsibility in sales, marketing and professional education at Ethicon Endo-Surgery and Karl Storz Endoscopy, America.
Mr. Stankovich has over 25 years of executive leadership experience as the CFO for multiple public and private healthcare companies. Tom has spent the past nine years as the Global Senior Vice President and CFO of MP Biomedicals, a life sciences and molecular biology-diagnostics company. At MP Biomedicals he was responsible for financial planning and reporting, financial operations and strategy development along with the acquisition and integration of two international companies. Prior to MP Biomedicals, Tom served as CFO at Response Genetics where he successfully led the company through their initial public offering. Additionally, he served as CFO for Cobalis Corporation and for Ribapharm, where he also led the company through their initial public offering, which at the time became the second largest ever IPO in the biotechnology sector. Tom also held CFO positions at ICN International, which later changed names to Valeant Pharmaceuticals.
Dr. Nihalani has served as Chief Technology Officer & Business Development since May 2017, immediately following the Company’s acquisition of BarioSurg, Inc. From August 2008 to May 2017, Dr. Nihalani served as the Chief Executive Officer of BarioSurg, Inc., a privately held medical device company that developed a minimally invasive and reversible device to treat obesity and glycemic control. Dr. Nihalani has several US and international patents and has won awards for his inventions. He holds a medical degree from the University of Nagpur, India. Also, he held positions of increased responsibility at Endologix (ELGX), Medtronic (MDT), Acufocus, Inc, Rox Medical, & TrialMed Life Sciences.
Mr. Condrin joined the Company as Senior Vice President, Commercial in May 2019. Mr. Condrin has over 25 years of global experience in Sales, Marketing, Business Development, Product Management, Procedure Development, and Training. Prior to joining ReShape Lifesciences, Kevin led the growth and development of numerous novel technologies and procedures primarily in the bariatric, endolumenal, laparoscopic, and advanced visualization spaces. In his many years as a medical device leader, he has held senior positions with increasing responsibilities while at USGI Medical, Medtronic, Covidien, Karl Storz, and Circon ACMI (now Olympus).
Mr. Shah joined the Company as Vice President of Operations and R&D in February 2018. With more than 20 years of experience in medical device manufacturing management, global supply chain, and information technology, he brings the business and technical requirements needed to ensure effective leadership and management. Prior to joining ReShape Lifesciences, Mr. Shah served as Vice President of Manufacturing and Operations at Presbia, where he oversaw global operations and manufacturing for optical medical device products, established the company’s manufacturing facility, and developed OEM overseas manufacturing. He has also held positions as Director of Manufacturing/Supply Chain for BiovisionAG/Visitome, Global Planning System Analyst at CooperVision, and Operations/IT Manager for Ocular Sciences.
Dr. Gal joined the Company as Vice President, Regulatory and Clinical Affairs in September 2019. With more than 30-year experience as a practicing veterinarian, academician at Tufts University School of Medicine and subsequently in the medtech industry. Prior to joining ReShape Lifesciences, Dr. Gal held R&D, clinical marketing and clinical affairs positions in private start-up, and medium to large public medical device companies. Specifically, Dr. Gal led the regulatory, clinical and quality departments at ClearFlow Inc., the clinical department of the Heart Valve Therapy business at Edwards Lifesciences, the clinical department at Broncus Technologies, and was the director of clinical research at Medtronic Vascular. Dr. Gal holds a BSc. degree in biology from Tel Aviv University, Tel Aviv Israel, Doctor of Veterinary Medicine degree from Pisa University, Pisa Italy, and an MBA degree from Boston University, Boston, Massachusetts.
Mr. Brendan O’Connell joined the Company in August 2019 as Vice President of Finance and Corporate Controller. Mr. O’Connell has over 20 years of accounting and finance experience, with over 12 years in the medical device space. Most recently, Mr. O’Connell served as Vice President of Finance and Corporate Controller for Biolase Incorporated. Mr. O’Connell holds a master’s degree from the University of California at Riverside.